Clinical Trial Update: Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 exploratory study evaluating the safety and feasibility of YTS109 cell therapy for multiple autoimmune diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antineutrophil Cytoplasmic Antibody-associated Vasculitis
• Antiphospholipid Syndrome
• Inflammatory Myopathy
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• YTS109 cell therapy (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Status: RECRUITING